Artiva Biotherapeutics, Inc. (ARTV)

Over the past six months, Artiva Biotherapeutics' stock (ARTV) has experienced significant volatility, with a 52-week range between $1.47 and $13.19. As of November 18, 2025, the share price was $3.89, representing a decline of 65.58% from $11.30 on November 19, 2024. Artiva Biotherapeutics released its quarterly earnings data on November 12, 2025, reporting ($0.88) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.04, and also reported second-quarter 2025 financial results on August 6, 2025. Several brokerage firms have issued ratings and price targets for ARTV, with an average rating of "Moderate Buy" and an average 12-month price objective of $19.00. On November 12, 2025, HC Wainwright & Co. maintained a "Buy" rating and raised its price target from $12.00 to $15.00. On October 17, 2025, Wedbush boosted its target price from $18.00 to $23.00 and gave the stock an "outperform" rating, and Needham & Company LLC restated a "buy" rating and set an $18.00 target price on the same day. Weiss Ratings reissued a "sell (d-)" rating on October 30, 2025. On October 17, 2025, CEO Fred Aslan sold 25,500 shares of the company's stock at an average price of $6.00. Artiva Biotherapeutics' lead candidate AlloNK received Fast Track Designation from the FDA for refractory rheumatoid arthritis.

There is no traditional demand seasonality for Artiva Biotherapeutics' products or services. The demand for its therapies is driven by medical need and the progression of clinical trials and regulatory approvals, rather than seasonal consumer patterns.

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel cell therapies for patients with autoimmune diseases and cancers. The company is dedicated to harnessing the power of allogeneic natural killer (NK) cells to address unmet medical needs. Its product candidates are off-the-shelf, derived from donor cells rather than a patient's own cells, pre-manufactured, stored frozen, and ready for shipment to treatment locations. Artiva's pipeline includes AlloNK (AB-101), an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the ADCC effect of monoclonal antibodies, being evaluated in clinical trials for B-cell driven autoimmune diseases and B-cell non-Hodgkin lymphoma, and has received Fast Track Designation from the FDA for refractory rheumatoid arthritis. AB-201 is an allogeneic anti-human epidermal growth factor receptor 2 (HER2) targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors. AB-205 is an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies.

Artiva Biotherapeutics, Inc. is headquartered in San Diego, California. The company manages and executes clinical trials for its NK cell therapy candidates, and has established strategic partnerships and collaborations with academic institutions and industry players.

Artiva Biotherapeutics has maintained a generally positive brand reputation among analysts, with a consensus rating of "Moderate Buy" or "Strong Buy" from several brokerage firms. The FDA Fast Track Designation for AlloNK in refractory rheumatoid arthritis enhances the company's standing and investment narrative. Despite ongoing financial challenges and the need for successful clinical trials, this designation positions the company favorably in the autoimmune treatment pipeline.

Artiva Biotherapeutics, Inc. has 115 institutional owners and shareholders who have filed 13D/G or 13F forms, holding a total of 19,606,975 shares. Major institutional owners include Ra Capital Management, L.P., 5AM Venture Management, LLC, VR Adviser, LLC, venBio Partners LLC, SMCWX - SMALLCAP WORLD FUND INC Class A, Citadel Advisors Llc, Franklin Resources Inc, BlackRock, Inc., Millennium Management Llc, and FSSNX - Fidelity Small Cap Index Fund. Insiders collectively own 21.40% of the company.